Biochemical modulation of cisplatin mechanisms of action:: Enhancement of antitumor activity and circumvention of drug resistance

被引:789
作者
Fuertes, MA [1 ]
Alonso, C
Pérez, JM
机构
[1] Univ Autonoma Madrid, Dept Quim Inorgan, Fac Ciencias, E-28049 Madrid, Spain
[2] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain
关键词
D O I
10.1021/cr020010d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Biochemical modulation concerns the manipulation of cellular biochemical pathways by chemical agents to produce selective enhancement of the efficacy of an antitumor drug such as cisplatin. Cisplatin is highly effective in the treatment of testicular and ovarian cancers. However, some tumors such as colorectal and nonsmall cell lung cancers have intrinsic resistance to cisplatin. This review gives an update of the state-of-the-art of the biochemical modulation of cisplatin mechanisms of resistance. It is emphasized that biochemical modulation of cisplatin mechanisms of resistance offers multiple opportunities for future applications in clinical cancer research.
引用
收藏
页码:645 / 662
页数:18
相关论文
共 174 条
  • [1] BINDING CHARACTERISTICS OF (-)-(R)-2-AMINOMETHYLPYRROLIDINE(1,1-CYCLOBUTANEDICARBOXYLATO)-2-PLATINUM(II) TO DNA, RNA AND PROTEIN MOLECULES IN HELA-CELLS AND ITS LETHAL EFFECT - COMPARISON WITH CIS- AND TRANS-DIAMMINEDICHLOROPLATINUMS(II)
    AKABOSHI, M
    KAWAI, K
    UJENO, Y
    TAKADA, S
    MIYAHARA, T
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (01): : 106 - 111
  • [2] THE NUMBER OF PLATINUM ATOMS BINDING TO DNA, RNA AND PROTEIN MOLECULES OF HELA-CELLS TREATED WITH CISPLATIN AT ITS MEAN LETHAL CONCENTRATION
    AKABOSHI, M
    KAWAI, K
    MAKI, H
    AKUTA, K
    UJENO, Y
    MIYAHARA, T
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (05): : 522 - 526
  • [3] ALIOSMAN F, 1993, CANCER RES, V53, P5663
  • [4] Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO
  • [5] 2-0
  • [6] Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1
  • [7] Andrews PA, 2000, CANC DRUG DISC DEV, V7, P89
  • [8] MAMMALIAN DEOXYRIBONUCLEOSIDE KINASES
    ARNER, ESJ
    ERIKSSON, S
    [J]. PHARMACOLOGY & THERAPEUTICS, 1995, 67 (02) : 155 - 186
  • [9] Auge P, 1997, TRANSIT METAL CHEM, V22, P91
  • [10] L-S,R-buthionine sulfoximine:: historical development and clinical issues
    Bailey, HH
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 112 : 239 - 254